268 related articles for article (PubMed ID: 17638903)
1. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
2. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR
Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136
[TBL] [Abstract][Full Text] [Related]
3. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
5. Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma.
Kumar A; Mandiyan V; Suzuki Y; Zhang C; Rice J; Tsai J; Artis DR; Ibrahim P; Bremer R
J Mol Biol; 2005 Apr; 348(1):183-93. PubMed ID: 15808862
[TBL] [Abstract][Full Text] [Related]
6. Discovery of imidazopyridazines as potent Pim-1/2 kinase inhibitors.
Wurz RP; Sastri C; D'Amico DC; Herberich B; Jackson CLM; Pettus LH; Tasker AS; Wu B; Guerrero N; Lipford JR; Winston JT; Yang Y; Wang P; Nguyen Y; Andrews KL; Huang X; Lee MR; Mohr C; Zhang JD; Reid DL; Xu Y; Zhou Y; Wang HL
Bioorg Med Chem Lett; 2016 Nov; 26(22):5580-5590. PubMed ID: 27769621
[TBL] [Abstract][Full Text] [Related]
7. Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma.
Yang Q; Chen LS; Neelapu SS; Miranda RN; Medeiros LJ; Gandhi V
Blood; 2012 Oct; 120(17):3491-500. PubMed ID: 22955922
[TBL] [Abstract][Full Text] [Related]
8. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of PIM-1 kinase: a computational analysis of the binding free energies of a range of imidazo [1,2-b] pyridazines.
Doudou S; Sharma R; Henchman RH; Sheppard DW; Burton NA
J Chem Inf Model; 2010 Mar; 50(3):368-79. PubMed ID: 20175582
[TBL] [Abstract][Full Text] [Related]
10. Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers.
Garcia PD; Langowski JL; Wang Y; Chen M; Castillo J; Fanton C; Ison M; Zavorotinskaya T; Dai Y; Lu J; Niu XH; Basham S; Chan J; Yu J; Doyle M; Feucht P; Warne R; Narberes J; Tsang T; Fritsch C; Kauffmann A; Pfister E; Drueckes P; Trappe J; Wilson C; Han W; Lan J; Nishiguchi G; Lindvall M; Bellamacina C; Aycinena JA; Zang R; Holash J; Burger MT
Clin Cancer Res; 2014 Apr; 20(7):1834-45. PubMed ID: 24474669
[TBL] [Abstract][Full Text] [Related]
11. New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights.
López-Ramos M; Prudent R; Moucadel V; Sautel CF; Barette C; Lafanechère L; Mouawad L; Grierson D; Schmidt F; Florent JC; Filippakopoulos P; Bullock AN; Knapp S; Reiser JB; Cochet C
FASEB J; 2010 Sep; 24(9):3171-85. PubMed ID: 20400536
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
[TBL] [Abstract][Full Text] [Related]
13. Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.
Tong Y; Stewart KD; Thomas S; Przytulinska M; Johnson EF; Klinghofer V; Leverson J; McCall O; Soni NB; Luo Y; Lin NH; Sowin TJ; Giranda VL; Penning TD
Bioorg Med Chem Lett; 2008 Oct; 18(19):5206-8. PubMed ID: 18790640
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of novel tyrosine kinase inhibitors using a pharmacophore model of the ATP-binding site of the EGF-R.
Traxler P; Furet P; Mett H; Buchdunger E; Meyer T; Lydon N
J Pharm Belg; 1997; 52(2):88-96. PubMed ID: 9193132
[TBL] [Abstract][Full Text] [Related]
16. Discovery of thiophene inhibitors of polo-like kinase.
Emmitte KA; Andrews CW; Badiang JG; Davis-Ward RG; Dickson HD; Drewry DH; Emerson HK; Epperly AH; Hassler DF; Knick VB; Kuntz KW; Lansing TJ; Linn JA; Mook RA; Nailor KE; Salovich JM; Spehar GM; Cheung M
Bioorg Med Chem Lett; 2009 Feb; 19(3):1018-21. PubMed ID: 19097784
[TBL] [Abstract][Full Text] [Related]
17. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.
Byth KF; Cooper N; Culshaw JD; Heaton DW; Oakes SE; Minshull CA; Norman RA; Pauptit RA; Tucker JA; Breed J; Pannifer A; Rowsell S; Stanway JJ; Valentine AL; Thomas AP
Bioorg Med Chem Lett; 2004 May; 14(9):2249-52. PubMed ID: 15081018
[TBL] [Abstract][Full Text] [Related]
18. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
19. A combination strategy to inhibit Pim-1: synergism between noncompetitive and ATP-competitive inhibitors.
Mori M; Tintori C; Christopher RS; Radi M; Schenone S; Musumeci F; Brullo C; Sanità P; Delle Monache S; Angelucci A; Kissova M; Crespan E; Maga G; Botta M
ChemMedChem; 2013 Mar; 8(3):484-96. PubMed ID: 23436791
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
